Sun, Jan 25, 2015, 6:33 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

AmpliPhi Biosciences Corporation Message Board

  • redspinelpinktopaz redspinelpinktopaz May 23, 2013 7:16 AM Flag


    I believe you are incorrect. AAV was sold to Genzyme, and everything arising from it except Mydicar and Glybera--and of course all Core Phage. But it should be enough. Cheers.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Hi red, this from the Genzyme AAV sale agreement seems to support the view that APHB could benefit? You'll notice that APHB/TGEN received back specifically the Huntington's AAV technology:

      "As part of the transaction, Targeted Genetics has agreed to work with Genzyme to transfer the acquired technology and assist Genzyme in its implementation of the technology. Genzyme has agreed to pay $3.5 million within five days of the closing and an additional $3.5 million in installments payable upon successful completion of specified transfer plan deliverables. Targeted Genetics expects the transition plan to be completed by the end of 2009. In addition, Targeted Genetics will receive revenue from Genzyme in the event that Genzyme sublicenses the acquired intellectual property within specified time periods, and will receive royalties in the event of commercial sales of products containing AAV vectors covered by the acquired intellectual property.

      As part of the transaction, Genzyme has licensed back to Targeted Genetics the AAV manufacturing and vector technology sold to Genzyme for Targeted Genetics' use in specified product programs, including the development and sale of products in Targeted Genetics' current AAV gene therapeutic programs for the treatment of a type of blindness called Leber's Congenital Amaurosis, inflammatory arthritis and a neurodegenerative disease called Huntington's Disease. Genzyme will receive royalties from Targeted Genetics in the event of any commercial sales of certain products utilizing the intellectual property licensed back to Targeted Genetics."

      Sentiment: Strong Buy

0.21+0.03(+16.67%)Jan 23 3:59 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.